The Malignant Pleural Mesothelioma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Malignant Pleural Mesothelioma Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Malignant Pleural Mesothelioma Market.

Some of the key takeaways from the Malignant Pleural Mesothelioma Pipeline Report:

• Companies across the globe are diligently working toward developing novel Malignant Pleural Mesothelioma treatment therapies with a considerable amount of success over the years. 
• Malignant Pleural Mesothelioma companies working in the treatment market are  AstraZeneca, Merck & Co, Inhibrx, Nurix Therapeutics, Atara Biotherapeutics, TCR2 Therapeutics, RS Oncology, Sanofi, MomotaroGene, and others, are developing therapies for the Malignant Pleural Mesothelioma treatment 

• Emerging Malignant Pleural Mesothelioma therapies such as – INBRX-109, NX-1607, ATA2271, TC-510, RSO-021, SAR-444245, MTG201, Durvalumab, Pembrolizumab, and others are expected to have a significant impact on the Malignant Pleural Mesothelioma market in the coming years.   
• In December 2022, efficacy and safety data from the phase II/III DENIM trial in Mesothelioma were released by Amphera
• In September 2022, Pegargiminase received Fast track status from the US FDA for Mesothelioma
• In June 2022, In the USA (Intratumoural), Momotaro-Gene announced that enrollment in their phase II trial for mesothelioma (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or larger) had reached its completion
• In March 2021, Merck & Co initiated a Pembrolizumab plus Lenvatinib in second line and third line Malignant Pleural mesothelioma patients (PEMMELA). Currently the trial is active, not recruiting However the primary completion date was August 2022 with 38 participants

Malignant Pleural Mesothelioma Overview

Malignant pleura Mesothelioma (MPM) is an aggressive cancer arising from the mesothelial cells of the pleura. The pleura is thin cellular lining than envelops both the lung (termed the “visceral” pleura) and chest wall (the “parietal” pleura), as well as the diaphragm, and the heart and major blood vessels in the central portion of the chest

Get a Free Sample PDF Report to know more about Malignant Pleural Mesothelioma Pipeline Therapeutic Assessment-

https://www.delveinsight.com/sample-request/malignant-pleural-mesothelioma-mpm-pipeline-insight

Emerging Malignant Pleural Mesothelioma Drugs Under Different Phases of Clinical Development Include:

• INBRX-109: Inhibrx
• NX-1607: Nurix Therapeutics
• NGR-TNF: MolMed
• ATA2271: Atara Biotherapeutics
• TC-510: TCR2 Therapeutics
• Pembrolizumab : Merck & Co
• Pegargiminase: Polaris Pharmaceuticals
• RSO-021: RS Oncology
• YS110: Ys Therapeutics
• Lurbinectedin: PharmaMar
• SAR-444245: Sanofi
• MTG201: MomotaroGene
• Durvalumab: AstraZeneca
• Pembrolizumab: Merck & Co

Route of Administration

Malignant Pleural Mesothelioma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Molecule Type

Products have been categorized under various Molecule types, such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Malignant Pleural Mesothelioma Pipeline Therapeutics Assessment

• Malignant Pleural Mesothelioma Assessment by Product Type
• Malignant Pleural Mesothelioma By Stage and Product Type
• Malignant Pleural Mesothelioma Assessment by Route of Administration
• Malignant Pleural Mesothelioma By Stage and Route of Administration
• Malignant Pleural Mesothelioma Assessment by Molecule Type
• Malignant Pleural Mesothelioma by Stage and Molecule Type

DelveInsight’s Malignant Pleural Mesothelioma Report covers around 20+ products under different phases of clinical development like-

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Malignant Pleural Mesothelioma product details are provided in the report. Download the Malignant Pleural Mesothelioma pipeline report to learn more about the emerging Malignant Pleural Mesothelioma therapies

Some of the key companies in the Malignant Pleural Mesothelioma Therapeutics Market include:

Key companies developing therapies for Malignant Pleural Mesothelioma are – Amphera BV, Polaris Pharmaceuticals, Sellas Life Sciences Group, Momotaro-Gene, PharmaMar, AstraZeneca, Targovax, TCR2 Therapeutics, Hoffmann-La Roche, Novartis,  MolMed, Ys Therapeutics, Merck Sharp & Dohme Corp., Kissei Pharmaceutical Co., Ltd., NovoCure Ltd, AGC Biologics S.p.A, Aduro Biotech, Inc, Bristol-Myers Squibb, Novotech (Australia) Pty Limited, Kyorin Pharmaceuticals, ACADIA Pharmaceuticals, and others.

Malignant Pleural Mesothelioma Pipeline Analysis:

The Malignant Pleural Mesothelioma pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Malignant Pleural Mesothelioma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Malignant Pleural Mesothelioma Treatment.
• Malignant Pleural Mesothelioma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Malignant Pleural Mesothelioma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Malignant Pleural Mesothelioma market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Malignant Pleural Mesothelioma drugs and therapies

Malignant Pleural Mesothelioma Pipeline Market Drivers

• Increased adoption of combination therapies are some of the important factors that are fueling the Malignant Pleural Mesothelioma Market.

Malignant Pleural Mesothelioma Pipeline Market Barriers

• However, treatment of unresectable malignant pleural mesothelioma (MPM) remains a challenging problem, high Cost of Treatment and other factors are creating obstacles in the Malignant Pleural Mesothelioma Market growth.

Scope of Malignant Pleural Mesothelioma Pipeline Drug Insight    

• Coverage: Global
• Key Malignant Pleural Mesothelioma Companies: AstraZeneca, Merck & Co, Inhibrx, Nurix Therapeutics, Atara Biotherapeutics, TCR2 Therapeutics, RS Oncology, Sanofi, MomotaroGene, and others
• Key Malignant Pleural Mesothelioma Therapies: INBRX-109, NX-1607, ATA2271, TC-510, RSO-021, SAR-444245, MTG201, Durvalumab, Pembrolizumab, and others
• Malignant Pleural Mesothelioma Therapeutic Assessment: Malignant Pleural Mesothelioma current marketed and Malignant Pleural Mesothelioma emerging therapies
• Malignant Pleural Mesothelioma Market Dynamics: Malignant Pleural Mesothelioma market drivers and Malignant Pleural Mesothelioma market barriers 

Request for Sample PDF Report for Malignant Pleural Mesothelioma Pipeline Assessment and clinical trials

Table of Contents

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

About DelveInsight 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services